Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMDPN6X)

Drug Name
VTX-11e Drug Info
Cross-matching ID
PubChem CID
11634725
ChEBI ID
CHEMBL95049
CAS Number
CAS 896720-20-0
TTD Drug ID
D0J3LR

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.22 0.00e+0 34/36 (94.44%) PRIM1;PCNA;MCM2;...
Mismatch repair 2.07 4.17e-3 22/23 (95.65%) PCNA;RFC4;MLH1;...
Cell cycle 1.93 5.56e-3 110/124 (88.71%) GADD45B;CCNB2;CDC20;...
Homologous recombination 1.90 6.25e-3 35/41 (85.37%) POLD1;RPA2;BARD1;...
Oxidative phosphorylation 1.90 5.00e-3 93/133 (69.92%) COX7A1;NDUFB4;NDUFS3;...
Valine, leucine and isoleucine degradation 1.89 4.17e-3 42/48 (87.5%) ALDH6A1;DLD;ALDH3A2;...
Proximal tubule bicarbonate reclamation 1.80 1.19e-2 21/23 (91.3%) ATP1B1;AQP1;ATP1A2;...
Protein processing in endoplasmic reticulum 1.79 1.15e-2 127/171 (74.27%) CRYAB;HSPA1A;DNAJB2;...
Propanoate metabolism 1.78 1.20e-2 30/34 (88.24%) ALDH6A1;DLD;ACACB;...
Protein export 1.77 1.08e-2 17/23 (73.91%) OXA1L;SRP9;SRPRB;...
Nucleotide excision repair 1.77 9.85e-3 40/47 (85.11%) DDB2;PCNA;RFC4;...
Tryptophan metabolism 1.70 2.92e-2 35/42 (83.33%) CYP1B1;DLD;MAOB;...
Spliceosome 1.68 3.14e-2 101/150 (67.33%) HSPA1A;HSPA2;HSPA8;...
Base excision repair 1.66 3.57e-2 29/33 (87.88%) HMGB1;PCNA;PARP2;...
Pyruvate metabolism 1.64 3.78e-2 41/47 (87.23%) ADH1B;DLD;MDH1;...
Protein digestion and absorption 1.62 4.48e-2 78/103 (75.73%) COL11A1;ATP1B1;CPA3;...
Citrate cycle (TCA cycle) 1.60 4.95e-2 30/30 (100%) IDH2;ACO2;DLD;...
Lysine degradation 1.58 4.92e-2 51/63 (80.95%) EZH2;DLD;ALDH3A2;...
GnRH signaling pathway -1.74 1.51e-2 80/93 (86.02%) HRAS;GNAS;PRKCB;...
AGE-RAGE signaling pathway in diabetic complications -1.75 1.48e-2 97/100 (97%) DIAPH1;F3;PIK3CB;...
Leishmaniasis -1.76 1.33e-2 67/77 (87.01%) ELK1;ITGB1;FCGR2C;...
Amoebiasis -1.76 1.38e-2 99/102 (97.06%) CXCL2;GNAS;PRKCB;...
Focal adhesion -1.76 1.44e-2 180/201 (89.55%) COL6A3;PAK2;COL9A3;...
Chemokine signaling pathway -1.76 1.49e-2 163/192 (84.9%) CCL11;NRAS;CCL7;...
NOD-like receptor signaling pathway -1.76 1.51e-2 145/181 (80.11%) PYCARD;CCL5;MAPK13;...
Phospholipase D signaling pathway -1.77 1.38e-2 134/148 (90.54%) ADCY1;AGPAT4;RAPGEF3;...
Ras signaling pathway -1.77 1.29e-2 201/232 (86.64%) NRAS;CSF1;RRAS;...
Neurotrophin signaling pathway -1.78 1.35e-2 107/119 (89.92%) SH2B2;NRAS;MAPK7;...
Human cytomegalovirus infection -1.80 1.02e-2 201/225 (89.33%) IL10RA;NRAS;PPP3R1;...
Mucin type O-glycan biosynthesis -1.83 8.93e-3 20/36 (55.56%) GALNT2;ST6GALNAC4;C1GALT1C1;...
Glycosaminoglycan biosynthesis -1.83 8.80e-3 40/58 (68.97%) CSGALNACT1;CHPF2;GLCE;...
ErbB signaling pathway -1.83 9.32e-3 79/85 (92.94%) PAK2;NCK1;SHC1;...
Proteoglycans in cancer -1.85 5.66e-3 172/205 (83.9%) PTCH1;PIK3CB;CD63;...
Salmonella infection -1.85 6.04e-3 198/249 (79.52%) DYNC1LI2;CD14;NCKAP1;...
Hematopoietic cell lineage -1.85 5.66e-3 90/99 (90.91%) CD8B;CSF2RA;CD14;...
Cytokine-cytokine receptor interaction -1.86 6.09e-3 246/295 (83.39%) TNFRSF25;CSF1R;CCL11;...
Kaposi sarcoma-associated herpesvirus infection -1.88 3.77e-3 172/193 (89.12%) NRAS;PPP3R1;CASP8;...
Epithelial cell signaling in Helicobacter pylori infect... -1.89 2.06e-3 62/70 (88.57%) IKBKB;PAK1;RAC1;...
Viral protein interaction with cytokine and cytokine re... -1.91 1.13e-3 84/100 (84%) CSF1R;CCL11;IL10RA;...
Pertussis -1.96 0.00e+0 64/76 (84.21%) CD14;C5;C2;...
Rheumatoid arthritis -1.97 0.00e+0 78/93 (83.87%) ACP5;TLR4;ICAM1;...
C-type lectin receptor signaling pathway -2.00 0.00e+0 93/104 (89.42%) NRAS;PPP3R1;CASP8;...
NF-kappa B signaling pathway -2.01 0.00e+0 90/104 (86.54%) TRIM25;CCL21;CCL13;...
Bladder cancer -2.01 0.00e+0 40/41 (97.56%) TYMP;RPS6KA5;MAPK3;...
Pathogenic Escherichia coli infection -2.05 0.00e+0 152/197 (77.16%) LPAR2;NCKAP1;RIPK1;...
TNF signaling pathway -2.10 0.00e+0 103/112 (91.96%) CSF1;CASP8;CXCL5;...
Yersinia infection -2.11 0.00e+0 120/137 (87.59%) MAPK10;ITGB1;ACTR2;...
IL-17 signaling pathway -2.16 0.00e+0 84/94 (89.36%) CCL11;MAPK7;CASP8;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-673 CVCL_0080 Homo sapiens 0.5uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.5uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CL-34 CVCL_1123 Homo sapiens 0.5uM 6H
HT-29 CVCL_0320 Homo sapiens 0.5uM 6H, 24H
LoVo CVCL_0399 Homo sapiens 0.5uM 6H
MDST8 CVCL_1400 Homo sapiens 0.5uM 6H
NCI-H508 CVCL_1561 Homo sapiens 0.5uM 6H
SNU-1040 CVCL_5001 Homo sapiens 0.5uM 6H
SNU-C4 CVCL_5008 Homo sapiens 0.5uM 6H
SNU-C5 CVCL_5009 Homo sapiens 0.5uM 6H
SW480 CVCL_0546 Homo sapiens 0.5uM 6H
SW620 CVCL_0547 Homo sapiens 0.5uM 6H
SW948 CVCL_0550 Homo sapiens 0.5uM 6H
Colorectal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCT 116 CVCL_0291 Homo sapiens 0.5uM 6H
HT115 CVCL_1294 Homo sapiens 0.5uM 6H
RKO CVCL_0504 Homo sapiens 0.5uM 6H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 0.5uM 6H
SNG-M CVCL_1707 Homo sapiens 0.5uM 6H
Endometrial carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHUEM-2 CVCL_1327 Homo sapiens 0.5uM 6H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.5uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.5uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.5uM 6H, 24H
DV-90 CVCL_1184 Homo sapiens 0.5uM 6H
SK-LU-1 CVCL_0624 Homo sapiens 0.5uM 6H
Lung adenosquamous carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H596 CVCL_1571 Homo sapiens 0.5uM 6H
Lung large cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COR-L23 CVCL_1133 Homo sapiens 0.5uM 6H
T3M-10 CVCL_1729 Homo sapiens 0.5uM 6H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC15 CVCL_1253 Homo sapiens 0.5uM 6H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1299 CVCL_0060 Homo sapiens 0.5uM 6H
HCC515 CVCL_5134 Homo sapiens 0.5uM 6H, 24H
NCI-H2073 CVCL_1523 Homo sapiens 0.5uM 6H
Small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1694 CVCL_1495 Homo sapiens 0.5uM 6H
NCI-H1836 CVCL_1502 Homo sapiens 0.5uM 6H
Lymph node
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
WSU-DLCL2 CVCL_1787 Homo sapiens 0.5uM 6H
Ovary
Ovarian carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
EFO-27 CVCL_1194 Homo sapiens 0.5uM 6H
OV7 CVCL_1623 Homo sapiens 0.5uM 6H
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
RMG-I CVCL_1663 Homo sapiens 0.5uM 6H
Ovarian mucinous cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COV644 CVCL_2011 Homo sapiens 0.5uM 6H
RMUG-S CVCL_1666 Homo sapiens 0.5uM 6H
Ovarian undifferentiated carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TYK-nu CVCL_1774 Homo sapiens 0.5uM 6H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.5uM 6H
Acute myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NOMO-1 CVCL_1609 Homo sapiens 0.5uM 6H
PL-21 CVCL_2161 Homo sapiens 0.5uM 6H
SKM-1 CVCL_0010 Homo sapiens 0.5uM 6H
Pleural effusion
Histiocytic lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-937 CVCL_0007 Homo sapiens 0.5uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.5uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 0.5uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.5uM 6H, 24H
SK-MEL-1 CVCL_0523 Homo sapiens 0.5uM 6H
SK-MEL-28 CVCL_0526 Homo sapiens 0.5uM 6H
Stomach
Gastric adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
AGS CVCL_0139 Homo sapiens 0.5uM 6H